Christopher A Mecoli1, Jamie Perin2, Jennifer E Van Eyk1,3, Jie Zhu3, Qin Fu1,3, Andrew G Allmon4, Youlan Rao4, Scott Zeger2, Fredrick M Wigley1, Laura K Hummers1, Ami A Shah5. 1. Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Ave, MFL Bldg, Center Tower, Suite 4100, Baltimore, MD, 21224, USA. 2. Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Room E3650, Baltimore, MD, 21205, USA. 3. Cedars-Sinai Medical Center, 127 S. San Vicente Blvd., Advanced Health Sciences Pavilion, 9th Floor, Los Angeles, CA, 90048, USA. 4. United Therapeutics, 1040 Spring Street, Silver Spring, MD, 20910, USA. 5. Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Ave, MFL Bldg, Center Tower, Suite 4100, Baltimore, MD, 21224, USA. Ami.Shah@jhmi.edu.
Abstract
INTRODUCTION: Although there is abundant evidence of vascular perturbation from studies of peripheral blood in systemic sclerosis (SSc), there are few data about the ability to use biomarkers of vascular injury and growth factors to predict vascular outcomes and response to therapy. We sought to explore the association between candidate vascular biomarkers and digital ulcerations (DU) in a clinical trial context. METHODS: We examined 19 circulating vascular, angiogenic, and inflammatory biomarkers in 124 patients with scleroderma and DU who participated in a randomized controlled trial of oral treprostinil diolamine (ClinicalTrials.gov identifier NCT00775463). Correlation, regression, and random forest analyses were conducted to assess biomarker relationships in response to drug treatment. RESULTS: Over the 20-week trial, 82 (66%) patients had their cardinal ulcer completely heal, 54 (44%) developed new ulcers, and 72 (58%) had complete healing of all ulcers; mean change in ulcer burden comparing week 20 with baseline was - 0.36 ± 1.70. Nineteen biomarkers were analyzed for their association and ability to predict clinical DU outcomes. After adjusting for multiple comparisons, no individual biomarker (baseline level, week 20 level, or change over time) was significantly associated with any of the clinical outcomes, suggesting that traditional vascular, angiogenic or inflammatory drivers are not predictive of ulcer fate. CONCLUSIONS: The lack of strong response to any of the vascular, angiogenic, or inflammatory markers suggest that these pathways are not primary drivers in the development of DU clinical outcomes in a SSc population with prevalent DU. KEY POINTS: • Currently we lack robust biomarkers to predict vascular outcomes or response to therapy in scleroderma patients with Raynaud's phenomenon.• Longitudinal assessment of vascular biomarkers in a clinical trial setting provides a unique opportunity to define biomarkers that predict vascular outcomes.• In a randomized controlled trial of oral treprostinil diolamine for treatment of scleroderma-associated digital ulcers, biomarkers involved in several vascular, inflammatory, and angiogenic pathways did not predict short-term clinical response to therapy or digital ulcer outcomes.• Further study of these and other biomarkers should be considered in Raynaud's clinical trials in scleroderma patients without prevalent digital ulcers.
RCT Entities:
INTRODUCTION: Although there is abundant evidence of vascular perturbation from studies of peripheral blood in systemic sclerosis (SSc), there are few data about the ability to use biomarkers of vascular injury and growth factors to predict vascular outcomes and response to therapy. We sought to explore the association between candidate vascular biomarkers and digital ulcerations (DU) in a clinical trial context. METHODS: We examined 19 circulating vascular, angiogenic, and inflammatory biomarkers in 124 patients with scleroderma and DU who participated in a randomized controlled trial of oral treprostinil diolamine (ClinicalTrials.gov identifier NCT00775463). Correlation, regression, and random forest analyses were conducted to assess biomarker relationships in response to drug treatment. RESULTS: Over the 20-week trial, 82 (66%) patients had their cardinal ulcer completely heal, 54 (44%) developed new ulcers, and 72 (58%) had complete healing of all ulcers; mean change in ulcer burden comparing week 20 with baseline was - 0.36 ± 1.70. Nineteen biomarkers were analyzed for their association and ability to predict clinical DU outcomes. After adjusting for multiple comparisons, no individual biomarker (baseline level, week 20 level, or change over time) was significantly associated with any of the clinical outcomes, suggesting that traditional vascular, angiogenic or inflammatory drivers are not predictive of ulcer fate. CONCLUSIONS: The lack of strong response to any of the vascular, angiogenic, or inflammatory markers suggest that these pathways are not primary drivers in the development of DU clinical outcomes in a SSc population with prevalent DU. KEY POINTS: • Currently we lack robust biomarkers to predict vascular outcomes or response to therapy in sclerodermapatients with Raynaud's phenomenon.• Longitudinal assessment of vascular biomarkers in a clinical trial setting provides a unique opportunity to define biomarkers that predict vascular outcomes.• In a randomized controlled trial of oral treprostinil diolamine for treatment of scleroderma-associated digital ulcers, biomarkers involved in several vascular, inflammatory, and angiogenic pathways did not predict short-term clinical response to therapy or digital ulcer outcomes.• Further study of these and other biomarkers should be considered in Raynaud's clinical trials in sclerodermapatients without prevalent digital ulcers.
Authors: Leandro De Oliveira; José C Peraçoli; Maria T Peraçoli; Henri Korkes; Giafranco Zampieri; Antonio F Moron; Nelson Sass Journal: Pregnancy Hypertens Date: 2013-04-23 Impact factor: 2.899
Authors: Ami A Shah; Elena Schiopu; Soumya Chatterjee; Mary Ellen Csuka; Tracy Frech; Avram Goldberg; Robert Spiera; Stanford L Peng; Ryan J McBride; Jody M Cleveland; Virginia Steen Journal: J Rheumatol Date: 2016-06-15 Impact factor: 4.666
Authors: J Wipff; J Avouac; D Borderie; D Zerkak; H Lemarechal; A Kahan; C Boileau; Y Allanore Journal: Rheumatology (Oxford) Date: 2008-05-13 Impact factor: 7.580
Authors: Ignacio Herraiz; Elisa Simón; Paula Isabel Gómez-Arriaga; José Manuel Martínez-Moratalla; Antonio García-Burguillo; Elena Ana López Jiménez; Alberto Galindo Journal: Int J Mol Sci Date: 2015-08-13 Impact factor: 5.923
Authors: Silvia Grignaschi; Anna Sbalchiero; Giuseppe Spinozzi; Bianca Lucia Palermo; Claudia Cantarini; Chantal Nardiello; Lorenzo Cavagna; Carla Olivieri Journal: Front Med (Lausanne) Date: 2022-08-18